Similar articles

• Drug labeling for teratogenicity: requirements of the U.S. Food and Drug Administration.

  Kelsey FO. Kelsey FO. Prog Clin Biol Res. 1985;163C:155-9. Prog Clin Biol Res. 1985. PMID: 3991617 No abstract available.
• [On the history of the Contergan (thalidomide) catastrophe in the light of drug legislation].

  Maio G. Maio G. Dtsch Med Wochenschr. 2001 Oct 19;126(42):1183-6. doi: 10.1055/s-2001-17888. Dtsch Med Wochenschr. 2001. PMID: 11607860 German. No abstract available.
• Thalidomide update: regulatory aspects.

  Kelsey FO. Kelsey FO. Teratology. 1988 Sep;38(3):221-6. doi: 10.1002/tera.1420380305. Teratology. 1988. PMID: 3227491 No abstract available.
• [Pharmacological principles in pregnancy].

  Villanueva LA, Valenzuela F. Villanueva LA, et al. Gac Med Mex. 1998 Sep-Oct;134(5):575-82. Gac Med Mex. 1998. PMID: 9842139 Review. Spanish.
• An overview of over the counter drugs in pregnancy and lactation.

  Das BP, Joshi M, Pant CR. Das BP, et al. Kathmandu Univ Med J (KUMJ). 2006 Oct-Dec;4(4):545-51. Kathmandu Univ Med J (KUMJ). 2006. PMID: 18603972 Review.